Understanding how HIV-1 mutations affect treatment with broadly neutralizing antibodies
Relevance of Resistance Mutations for the Susceptibility to Broadly Neutralizing Antibodies Against HIV-1
This study is looking at how certain changes in the HIV-1 virus can affect how well new treatments called broadly neutralizing antibodies work for people with HIV, especially in areas like sub-Saharan Africa, to help improve care for everyone living with the virus.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10902029 on NIH RePORTER |
What this research studies
This research investigates how certain mutations in the HIV-1 virus can impact the effectiveness of broadly neutralizing antibodies (bNAbs) in treating HIV infections. The study focuses on HIV-1 subtypes that are more common in regions like sub-Saharan Africa, rather than the subtype prevalent in North America and Europe. By analyzing blood samples from HIV-infected individuals, researchers will use advanced sequencing techniques to identify both common and rare mutations that may contribute to resistance against bNAbs. This approach aims to fill a critical knowledge gap and improve treatment strategies for diverse populations affected by HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young individuals (0-21 years old) who are HIV-positive and infected with non-subtype B strains of the virus.
Not a fit: Patients with subtype B HIV-1 infections, which are more common in North America and Europe, may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV treatments that are tailored to the specific mutations present in different HIV-1 subtypes.
How similar studies have performed: Previous research has shown promising results in understanding resistance mechanisms in HIV, but this specific focus on non-subtype B strains and the use of deep sequencing represents a novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Jilg, Nikolaus — Massachusetts General Hospital
- Study coordinator: Jilg, Nikolaus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.